OverviewSuggest Edit

Salarius Pharmaceuticals is a clinical-stage biotechnology company developing epigenetic-based cancer treatments. It develops Seclidemstat (SP-2577), which is in Phase I/II clinical trial for the treatment of advanced solid tumors, including prostate, breast, and ovarian cancers, as well as Ewing sarcoma.
TypePublic
Founded2011
HQHouston, TX, US
Websitesalariuspharma.com

Latest Updates

Employees (est.) (Dec 2019)7
Revenue (FY, 2020)$5.2 M(+52%)
Share Price (Sept 2021)$1.1(-2%)
Cybersecurity ratingBMore

Key People/Management at Salarius Pharmaceuticals

David J. Arthur

David J. Arthur

President and Chief Executive Officer
Mark J. Rosenblum

Mark J. Rosenblum

Chief Financial Officer
Philip Bauer

Philip Bauer

Vice President, Chemistry, Manufacturing & Control
Nadeem Q. Mirza

Nadeem Q. Mirza

Senior Vice President, Clinical Development
William McVicar

William McVicar

Chairman, Board of Directors
Rebecca Griffith-Eskew

Rebecca Griffith-Eskew

Vice President, Clinical Operations
Show more

Salarius Pharmaceuticals Office Locations

Salarius Pharmaceuticals has an office in Houston
Houston, TX, US (HQ)
Jp Mcgovern Building, 2450 Holcombe Blvd Suite J-608Houston
Show all (1)

Salarius Pharmaceuticals Financials and Metrics

Salarius Pharmaceuticals Revenue

Salarius Pharmaceuticals's revenue was reported to be $5.23 m in FY, 2020
USD

Revenue (FY, 2020)

5.2m

Net income (FY, 2020)

(7.4m)

EBIT (FY, 2020)

(7.8m)

Market capitalization (7-Sept-2021)

49.2m

Closing stock price (7-Sept-2021)

1.1

Cash (31-Dec-2020)

11.1m

EV

38.6m
Salarius Pharmaceuticals's current market capitalization is $49.2 m.
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Revenue

1.3m838.1k3.5m5.2m

Revenue growth, %

(34%)313%

Cost of goods sold

506.5k430.8k

Gross profit

768.0k407.4k
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

178.6k245.5k251.0k105.0k164.7k874.9k1.1m1.2m1.4m

Cost of goods sold

83.9k179.9k91.9k47.3k36.1k

Gross profit

94.6k65.6k159.1k57.6k128.6k

Gross profit Margin, %

53%27%63%55%78%
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Cash

19.2m9.8m3.7m11.1m

Accounts Receivable

10.4k9.9k3.9m

Prepaid Expenses

777.1k162.1k955.9k822.1k

Inventories

431.9k186.9k
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Cash

21.9m15.8m13.0m7.3m6.5m4.0m9.6m7.2m9.6m

Accounts Receivable

12.6k17.3k21.0k9.1k28.3k591.1k1.8m3.2m

Prepaid Expenses

1.3m856.1k478.7k675.3k436.0k1.2m646.4k339.9k1.1m

Inventories

418.2k275.7k223.5k164.6k130.9k
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(34.4m)(21.9m)(6.9m)(7.4m)

Depreciation and Amortization

324.5k228.2k127.4k18.1k

Inventories

22.2k228.0k1.2k

Accounts Payable

819.4k(1.7m)(519.3k)(2.8k)
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Net Income

(8.2m)(17.3m)(19.9m)(2.2m)(3.6m)(5.1m)(2.1m)(3.9m)(5.6m)

Depreciation and Amortization

64.1k124.0k177.0k36.5k46.5k123.2k4.2k8.5k12.7k

Inventories

(3.3k)139.2k191.4k22.3k56.0k1.2k

Accounts Payable

237.0k(859.1k)(725.2k)(156.2k)463.0k(593.4k)(911.3k)(741.0k)(607.9k)
USDFY, 2017

Financial Leverage

1.2 x
Show all financial metrics

Salarius Pharmaceuticals Cybersecurity Score

Cybersecurity ratingPremium dataset

B

86/100

SecurityScorecard logo

Salarius Pharmaceuticals Online and Social Media Presence

Embed Graph

Salarius Pharmaceuticals News and Updates

Salarius Pharmaceuticals to Present at the Virtual H.C. Wainwright 23rd Annual Global Investment Conference

HOUSTON, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pediatric cancers, and other hematologic and solid tumors, announced today that David Arthur, Chief E…

Salarius Pharmaceuticals to Present at the Virtual Diamond Equity Research Emerging Growth Invitational

HOUSTON, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pediatric cancers, and other hematologic and solid tumors, announced today that David Arthur, Chief Ex…

Salarius Pharmaceuticals Reports Second Quarter 2021 Financial Results and Highlights Recent Company Progress

Clinical Trial in Hematologic Cancers Initiated and Initial Patients Enrolled in Expanded Sarcoma Clinical Trial; Multiple Potential Data Readouts Expected in 2021 and 2022

Salarius Pharmaceuticals to Report Second Quarter 2021 Financial Results

Conference Call and Live Audio Webcast Scheduled for Thursday, August 5, 2021, 10:00 a.m. ET Conference Call and Live Audio Webcast Scheduled for Thursday, August 5, 2021, 10:00 a.m. ET

Salarius Pharmaceuticals Announces Aundrietta Duncan, Ph.D., To Present During Virtual Epigenetic Therapeutic Targets Summit

Dr. Duncan will discuss seclidemstat’s potential in treating FET-rearranged sarcomas Dr. Duncan will discuss seclidemstat’s potential in treating FET-rearranged sarcomas

Salarius Pharmaceuticals to Present at the Virtual Ladenburg Thalmann Healthcare Conference

HOUSTON, July 09, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, announced today that David Arthur, Chief Executive Officer, …
Show more

Salarius Pharmaceuticals Blogs

Salarius Pharmaceuticals to Host Virtual Key Opinion Leader and Investor Event

Salarius Pharmaceuticals to Host Virtual Key Opinion Leader and Investor Event Content Import Thu, 06/10/2021 - 13:30 Salarius Pharmaceuticals to Host Virtual Key Opinion Leader and Investor Event 06/10/21 This release is a backfill from a News Wire …

Salarius Pharmaceuticals Discloses Key Findings from Three Abstracts to be Presented at American Society of Clinical Oncology (ASCO) 2021 Annual Meeting

Preliminary drug activity observed in both relapsed/refractory Ewing sarcoma and Advanced Solid Tumor (AST) trials Presentations include full data from dose-escalation stage of Phase 1/2 clinical trial evaluating seclidemstat in Ewing sarcoma and preliminary data from ongoing AST trial HOUSTON ,

Salarius Pharmaceuticals Reports First Quarter Financial Results with Business Highlights

Cash and Cash Equivalents of $36.6M , More Than Sufficient to Fund Completion of the Current Clinical Trials of Lead Drug Candidate, Seclidemstat Conference Call and Live Audio Webcast Scheduled for Today, Wednesday, May 12, 2021 , 5:00 p.m. ET HOUSTON , May 12, 2021 (GLOBE NEWSWIRE) -- Salarius

Salarius Completes Dose-Escalation Stage of Phase 1/2 Clinical Trial in Relapsed and Refractory Ewing Sarcoma Patients, Initiates Expansion Stage in Ewing and Ewing-Related Sarcoma Patients

Salarius Completes Dose-Escalation Stage of Phase 1/2 Clinical Trial in Relapsed and Refractory Ewing Sarcoma Patients, Initiates Expansion Stage in Ewing and Ewing-Related Sarcoma Patients Content Import Wed, 02/17/2021 - 07:32 Salarius Completes Dose-Escalation Stage of Phase 1/2 Clinica…

Salarius Announces Exercise Of Warrants For $3.5 Million Of Gross Proceeds To Be Used For Ongoing Development Of Seclidemstat

HOUSTON , Dec. 11, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, today announced that it has entered into agreements with

Salarius Pharmaceuticals Reports Business Highlights and Third Quarter 2020 Financial Results

Salarius Pharmaceuticals Reports Business Highlights and Third Quarter 2020 Financial Results Content Import Wed, 11/11/2020 - 16:06 Salarius Pharmaceuticals Reports Business Highlights and Third Quarter 2020 Financial Results 11/11/20 This release is a backf…
Show more

Salarius Pharmaceuticals Frequently Asked Questions

  • When was Salarius Pharmaceuticals founded?

    Salarius Pharmaceuticals was founded in 2011.

  • Who are Salarius Pharmaceuticals key executives?

    Salarius Pharmaceuticals's key executives are David J. Arthur, Mark J. Rosenblum and Philip Bauer.

  • How many employees does Salarius Pharmaceuticals have?

    Salarius Pharmaceuticals has 7 employees.

  • What is Salarius Pharmaceuticals revenue?

    Latest Salarius Pharmaceuticals annual revenue is $5.2 m.

  • What is Salarius Pharmaceuticals revenue per employee?

    Latest Salarius Pharmaceuticals revenue per employee is $747.6 k.

  • Who are Salarius Pharmaceuticals competitors?

    Competitors of Salarius Pharmaceuticals include Medicenna Therapeutics, MetaStat and ImmunoCellular Therapeutics.

  • Where is Salarius Pharmaceuticals headquarters?

    Salarius Pharmaceuticals headquarters is located at Jp Mcgovern Building, 2450 Holcombe Blvd Suite J-608Houston, Houston.

  • Where are Salarius Pharmaceuticals offices?

    Salarius Pharmaceuticals has an office in Houston.

  • How many offices does Salarius Pharmaceuticals have?

    Salarius Pharmaceuticals has 1 office.